1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. Liver Diseases Therapeutics Market, by Treatment
6.1. Introduction
6.2. Anti Viral Drugs
6.3. Chemotherapy Drugs
6.4. Corticosteroids
6.5. Immunoglobulin
6.6. Immunosuppressant Drugs
6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End User
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Hospitals

8. California Liver Diseases Therapeutics Market

9. Florida Liver Diseases Therapeutics Market

10. Illinois Liver Diseases Therapeutics Market

11. New York Liver Diseases Therapeutics Market

12. Ohio Liver Diseases Therapeutics Market

13. Pennsylvania Liver Diseases Therapeutics Market

14. Texas Liver Diseases Therapeutics Market

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. AstraZeneca plc
16.2. Bayer AG
16.3. F. Hoffmann-La Roche AG
16.4. Gilead Science Inc.
16.5. GlaxoSmithKline plc
16.6. Johnson & Johnson Private Limited
16.7. Merck & Co. Inc.
16.8. Novartis AG
16.9. Pfizer Inc.
16.10. Sanofi

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 4. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
FIGURE 5. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2026
FIGURE 7. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, 2018-2026 (USD MILLION)
FIGURE 8. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 9. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2026 (USD MILLION)
FIGURE 10. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 11. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2026 (USD MILLION)
FIGURE 14. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 15. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, 2018-2026 (USD MILLION)
FIGURE 16. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 17. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2026 (USD MILLION)
FIGURE 18. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 19. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 20. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2026
FIGURE 22. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2026 (USD MILLION)
FIGURE 23. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 24. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 25. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 26. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 27. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 28. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES LIVER DISEASES THERAPEUTICS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY STATE, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY STATE, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: SCORES
TABLE 15. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 16. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 17. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: RANKING
TABLE 18. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 19. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 20. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 21. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 22. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 23. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 24. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

AstraZeneca plc
Bayer AG
F. Hoffmann-La Roche AG
Gilead Science Inc.
GlaxoSmithKline plc
Johnson & Johnson Private Limited
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi